The world’s largest diabetes conference will convene June 5–8 in New Orleans, Louisiana, offering a robust scientific program highlighting emerging science shaping the future of diabetes prevention and care, opportunities to connect with colleagues and industry experts, and actionable insights to put into clinical practice.
Investigators will present new clinical trial data each day at the 2026 Scientific Sessions of the American Diabetes Association® (ADA).
“Late-breaking clinical trial sessions are a cornerstone of the Scientific Sessions and remain among the most highly anticipated presentations,” said Scientific Sessions Meeting Planning Committee Chair Mark A. Atkinson, PhD. “Attendees will hear high-impact clinical trial results, with nearly a dozen sessions scheduled this year. The Planning Committee receives many submissions for these limited slots and evaluates each carefully for novelty and potential impact.”
Glucagon-like peptide-1 (GLP-1)-based therapies will be a frequent topic of discussion throughout the meeting and the clinical trial results sessions.
“We’re seeing an extraordinary pace of innovation, with GLP‑1-based therapies—including dual and triple agonists, oral agents, and longer acting formulations—moving rapidly through late‑stage clinical development,” said Marlon Pragnell, PhD, the ADA’s Vice President of Research and Science. “Alongside this progress, we’re seeing breakthroughs in type 1 diabetes that include immune‑based strategies and advances in cell engineering to protect and restore insulin‑producing cells. Together, these developments are reshaping how we think about modifying disease and point to a future with more durable, biology‑driven solutions.”
This year’s lineup of late-breaking clinical trial sessions includes:
June 5
- Amylin as a Novel Diabetes and Obesity Therapy
- Dual Agonism in Type 1 Diabetes: Unveiling Efficacy and Safety of Adjunct Therapy with CT-868 (GLP-1/GIP RA) in Adults with Type 1 Diabetes—Phase 1 and 2 Results
June 6
- The VESPER-1, -2 and -3 Trials of MET-097 (PF-08653944), an Ultra-Long-Acting GLP-1 Receptor Agonist for Weight Management
- Unlocking the Next Frontier in Treatment of Obesity and Type 2 Diabetes with Restitutive: A Triple Agonist, Activating the GIP, GLP-1 and Glucagon Receptors (TRANSCEND-T2D-1 and TRIUMPH-1 Results)
June 7
- The AIDING Trial: Automated Insulin Delivery in the Hospital—Results and Implications for Inpatient Diabetes Care
- REIMAGINE 1, 2, 3: Leveraging Amylin and GLP-1 for Type 2 Diabetes Care with CagriSema
- The Benefits of Glucagon/GLP-1 Receptor Dual Agonism: Insights from the SYNCHRONIZE™ Phase 3 Studies of Survodutide
June 8
- From Pen to Pill: Achieving a Paradigm Shift in Type 2 Diabetes—The Orforglipron “ACHIEVE” Clinical Trial Program
- AZD5004, A Novel Oral Small Molecule GLP-1 Receptor Agonist: Overweight/Obesity (VISTA) and Type 2 Diabetes (SOLSTICE) Phase 2 Trial Results
“The significant progress we’re seeing in clinical trials was largely driven by decades of foundational basic science research, much of which was presented at past ADA Scientific Sessions,” Dr. Atkinson noted. “Without those advances, we would not be where we are today. This meeting will feature numerous basic science presentations that are poised to shape future generations through improvements in understanding biology, new drug designs, and emerging therapeutic approaches.”
Through the Online Planner, prospective attendees can browse the program by date, session type, or topic.
Register Today for the 2026 Scientific Sessions
Register to join us in New Orleans June 5–8 to learn about the latest advances in diabetes research, prevention, and care. After the meeting, registered participants will have on-demand access to recorded presentations.
